Table 2:
Association between diuretic prescription and mortality/hospitalization outcomes, restricted to patients with dialysis vintage <1 year.
| Variables | n (%) | All-cause mortality | All-cause hospitalization | Hospitalization due to MACE + HF | Hospitalization due to HF | Hospitalization due to fracture |
|---|---|---|---|---|---|---|
| Events, n | 3078 | 8648 | 2629 | 936 | 421 | |
| Event rate per 100 patient-years | 10.6 | 45.0 | 9.5 | 3.3 | 1.5 | |
| Patient diuretic use, HR (95% CI) | ||||||
| Yes | 12 070 (38.2) | 1.04 (0.95–1.13) | 1.03 (0.98–1.08) | 1.06 (0.97–1.15) | 1.06 (0.92–1.23) | 0.88 (0.71–1.09) |
| No | 19 551 (61.8) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Patient loop diuretic dose (mg/day), HR (95% CI) | ||||||
| No dose | 20 234 (72.3) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| 0–≤60 | 2084 (7.5) | 1 (0.87–1.16) | 1.03 (0.96–1.11) | 1.2 (1.05–1.37) | 1.22 (0.97–1.54) | 0.94 (0.67–1.33) |
| 60–≤200 | 2827 (10.1) | 1.02 (0.91–1.15) | 1.08 (1.01–1.16) | 1.06 (0.94–1.2) | 1.13 (0.93–1.37) | 0.77 (0.55–1.06) |
| >200 | 2853 (10.2) | 1.13 (1–1.26) | 1.11 (1.03–1.18) | 1.05 (0.92–1.18) | 1.06 (0.85–1.32) | 1.04 (0.78–1.4) |
HR (95% CI) of each outcome shown for diuretic use (yes versus no) and loop diuretic dose (reference group: no dose). Doses of torsemide (4:1) and bumetanide (80:1) were converted to oral furosemide-equivalent doses. Cox models stratified by DOPPS phase and country and adjusted for age, sex, Black race, <90 days dialysis vintage, catheter use, BMI, serum albumin, haemoglobin and 13 comorbidities.